HomeBUSINESS
BUSINESS

World’s 1st Commercial Manufacturing Plant for Allogeneic iPSC Therapies Completed: Sumitomo Dainippon
(Mar.2.2018)

Factory Worker Culturing iPS Cell-Derived Cells
Sumitomo Dainippon Pharma said on March 1 that it has completed the construction of what it claims to be the world’s first facility dedicated to the commercial manufacturing of regenerative medicines and cell therapies derived from allogeneic iPS cells ...
(LOG IN FOR FULL STORY)

News Calendar